Avanos Medical (NYSE:AVNS) Sets New 1-Year High – Here’s What Happened

Shares of Avanos Medical, Inc. (NYSE:AVNS) reached a new 52-week high during trading on Friday . The stock traded as high as $24.75 and last traded at $24.7350, with a volume of 132581 shares trading hands. The stock had previously closed at $24.71.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. Weiss Ratings upgraded shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Finally, Wall Street Zen lowered shares of Avanos Medical from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce”.

Avanos Medical Stock Down 0.1%

The company’s fifty day moving average price is $15.70 and its 200-day moving average price is $13.23. The stock has a market cap of $1.15 billion, a P/E ratio of -15.63 and a beta of 1.05. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15.

Avanos Medical (NYSE:AVNS) last released its earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.05. The firm had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.70 million. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The business’s revenue was up .7% on a year-over-year basis. During the same quarter last year, the business earned $0.43 EPS. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Equities analysts forecast that Avanos Medical, Inc. will post 1.07 EPS for the current year.

Institutional Investors Weigh In On Avanos Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Louisiana State Employees Retirement System bought a new stake in Avanos Medical during the 1st quarter valued at about $289,000. Corient Private Wealth LLC purchased a new position in Avanos Medical during the 4th quarter valued at about $234,000. Alpine Global Management LLC purchased a new position in Avanos Medical during the 4th quarter valued at about $177,000. Vident Advisory LLC purchased a new position in Avanos Medical during the 4th quarter valued at about $585,000. Finally, State of Tennessee Department of Treasury increased its position in Avanos Medical by 50.0% during the 4th quarter. State of Tennessee Department of Treasury now owns 41,405 shares of the company’s stock valued at $465,000 after purchasing an additional 13,799 shares during the period. Institutional investors own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.